Table 1.
Characteristics of the included RCTs.
| Author and year | Diagnosis | Population | Mean age | SR = F/M | PD/CAL | ATB, dose, duration | Description of the intervention | Outcome (comparing the test group with the control group) | Follow- up | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hans [10] 2015 | Moderate-to-severe periodontitis | 180 | [35, 75] | - | ≥5 mm | MTZ (400 mg/thrice a day) for 10 d | SRP + placebo | FDIS + placebo | SRP + MET | FDIS + MET | MP: significant reduction of PG and TF just in the FDIS + MET group after 3 and 12 months | 12 months | ||
| Martande et al. [11] 2016 | Moderate-to-severe periodontitis | 70 | [25, 45] | — | >6 mm | Az (500 mg/once a day) for 3 d | SRP | SRP + AZ | CP: significant reduction of CAL and PD in the AZ group (p < 0.001) MP: significant reduction of subject positive to AA in the AZ group (p < 0.0001) |
12 months | ||||
| Borges et al. [12] 2017 | Severe ChP | 110 | ≤30 years | 62/47 | ≥4 mm | AMX (500 mg/thrice a day)+ MTZ (250 mg/thrice a day) 7 or 14 d | AMX (500 mg/thrice a day)+ MTZ (400 mg/thrice a day) 7 or 14 d | SRP + placebo | SRP + AMX + 250 mg of MTZ for 7 d | SRP + AMX + 250 mg of MTZ for 14 d | SRP + AMX + 400 mg of MTZ for 7 d | SRP + AMX + 400 mg of MTZ for14 d | CP: significant reduction of CP in groups AMX + MET for 14 days compared to those for 7 days | 12 months |
| Bechara Andere et al. [13] 2017 | GAgP | 40 | 32.2 | 38/2 | ≥6 sites, PD ≥ 5 mm and ≥2 sites, PD ≥ 7 mm | CLM (500 mg twice daily) for 3 d | FMUD + placebo | FMUD + CLM | CP: significant reduction in PD in sites with PD ≥ 7 mm after 6 months MP: significant reduction of PG and AA after 6 months |
6 months | ||||
| Ramiro et al. [14] 2018 | GChP | 59 | ≤30 years | 36/23 | ≥5 mm | MTZ (400 mg/thrice a day) for 14 d | AMX (500 mg/thrice a day)+ MTZ (400 mg/thrice a day) for 14 d | SRP | SRP + MET | SRP + AMX + MET | MP: significant reduction of sites colonized by archaea with lower level in pockets with PD < 6 mm | 6 months | ||
| Suryaprasanna et al. [15] 2018 | ChP | 30 | [30,50] | ≥5 mm | CLM (500 mg thrice daily) for 7 d | SRP | SRP + CLM | CP and BP: reduction of GI, CAL, and CRP but not in a significant way MP: significant reduction of AA and PG after 3 months but not 6 months |
6 months | |||||
| Ardila et al. [16] 2020 | GAgP | 36 | ≤30 years | 23/13 | ≥5 mm | MOX (400 mg/once a day) for 7 d | AMX (500 mg/thrice a day)+ MTZ (500 mg/thrice a day) for 7 d | SRP | SRP + MOX | SRP + AMX + MET | CP: significant reduction of PD and CAL for PD ≥ 6 mm at 6 months MP: AA reduction significantly at 6 months |
6 months | ||
| 524 | ||||||||||||||
CAL = clinical attachment level, PD = probing depth, GI = gingival index, CRP= C-reactive protein, CLM= clarithromycin, FMUD = full-mouth ultrasonic debridement, AMX = amoxicillin, MTZ = metronidazole, MOX = moxifloxacin, SRP = scaling and root planing, FDIS = full-mouth disinfection, PG= Porphyromonas gingivalis, TF = Tannerella forsythia, and AA = Aggregatibacter actinomycetemcomitans.